

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-A**

For Registration of Certain Classes of Securities  
Pursuant to Section 12(b) or (g) of the  
Securities Exchange Act of 1934

**MONOPAR THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of Incorporation)

**32-0463781**  
(I.R.S. Employer Identification No.)

**1000 Skokie Blvd., Suite 350**  
**Wilmette, Illinois**  
(Address of principal executive offices)

**60091**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

**Title of each class to be so registered**  
**Common Stock, par value \$0.001 per share**

**Name of each exchange on which each class is to be registered**  
**The NASDAQ Stock Market LLC**

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement file number to which this form relates (if applicable):**333-233303**

Securities to be registered pursuant to Section 12(g) of the Act:**None**

---

**Item 1. Description of Registrant's Securities to be Registered.**

Monopar Therapeutics Inc. (the "Registrant") hereby incorporates by reference the description of its Common Stock, \$0.001 par value per share, to be registered hereunder, contained under the heading "Description of Capital Stock" in the Registrant's Registration Statement on Form S-1 (File No. 333-233303), as originally filed with the Securities and Exchange Commission (the "Commission") on August 15, 2019, as amended (the "Registration Statement"). In addition, all of the above-referenced descriptions included in any prospectus relating to the Registration Statement filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits, no exhibits are filed herewith or incorporated herein by reference.

---

**Signature**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

**Monopar Therapeutics Inc**

Date: September 30, 2019

By: /s/ Chandler D. Robinson

Name: Chandler D. Robinson

Title: Chief Executive Officer

---